Yahoo Finance • 16 hours ago
In trading on Thursday, shares of Plains All American Pipeline LP (Symbol: PAA) entered into oversold territory, changing hands as low as $16.11 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a... Full story
Yahoo Finance • 8 days ago
Insmed Incorporated (NASDAQ:INSM) is among the most promising biotech stocks to buy according to hedge funds. In the second quarter, Public Employees Retirement System of Ohio acquired a new stake in Insmed Incorporated (NASDAQ:INSM) throu... Full story
Yahoo Finance • 10 days ago
Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story
Yahoo Finance • 10 days ago
We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Insmed Incorporated is one of them. Insmed Incorporated (NASDAQ:INSM) tops our list for being one of the best performing stocks. It is a biopharmace... Full story
Yahoo Finance • 18 days ago
Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. This momentum model looks fo... Full story
Yahoo Finance • 18 days ago
—Data from Phase 2b Study of Treprostinil Palmitil Inhalation Powder in Patients with Pulmonary Arterial Hypertension to be Presented at Late-Breaking ALERT Session— —New Analysis from Phase 3 ASPEN Trial Examines Efficacy and Safety of B... Full story
Yahoo Finance • 22 days ago
Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for... Full story
Yahoo Finance • 27 days ago
Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology scree... Full story
Yahoo Finance • last month
Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology scree... Full story
Yahoo Finance • last month
Below is Validea's guru fundamental report for INSMED INC (INSM). Of the 22 guru strategies we follow, INSM rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology scree... Full story
Yahoo Finance • last month
United Therapeutics stock catapulted Tuesday, pulling shares of rivals Insmed and Liquidia higher, on positive test results in IPF. Continue Reading View Comments... Full story
Yahoo Finance • 2 months ago
[Medical industry stock market graph chart] Rasi Bhadramani Hedge funds increased their overweight positioning in health care (NYSEARCA:XLV [https://seekingalpha.com/symbol/XLV]) despite a 7% decline in the sector during the second quarte... Full story
Yahoo Finance • 2 months ago
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Elevate Your Investing Strategy: Take advantage of TipR... Full story
Yahoo Finance • 2 months ago
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases, finds itself at a critical juncture following recent clinical trial results and strategi... Full story
Yahoo Finance • 2 months ago
[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Morgan Stanley downgraded Insmed (NASDAQ:INSM [https://seekingalpha.com/symbol/INSM]) to Equal Weight from Overweight on Wednesday, citing concerns over the biotech’s valuation, a... Full story
Yahoo Finance • 2 months ago
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung condition. Continue Reading View Comments... Full story
Yahoo Finance • 2 months ago
Earnings Call Insights: Insmed Incorporated (INSM) Q2 2025 MANAGEMENT VIEW * William H. Lewis, President, CEO & Chairman, highlighted, "Insmed is now three for three, all three of our late-stage assets, ARIKAYCE, brensocatib and TPIP a... Full story
Yahoo Finance • 2 months ago
* Insmed (NASDAQ:INSM [https://seekingalpha.com/symbol/INSM]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. * The consensus EPS Estimate is -$1.31 [https://seekingalpha.com/symbol/INSM/earnin... Full story
Yahoo Finance • 2 months ago
NetworkNewsWire Editorial Coverage NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than... Full story
Yahoo Finance • 2 months ago
Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a... Full story